As a Free StocksGuide user, you can view scores for all 7,052 stocks worldwide.
11 Analysts have issued a Forte Biosciences Inc forecast:
11 Analysts have issued a Forte Biosciences Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -44 -44 |
17%
17%
|
|
| EBIT (Operating Income) EBIT | -44 -44 |
17%
17%
|
|
| Net Profit | -42 -42 |
17%
17%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Forte Biosciences, Inc. engages in the development of biopharmaceutical products. It is a clinical stage dermatology company focuses in the treatment of inflammatory skin diseases. It offers FB-401, a live bio-therapeutic product. The company was founded by Paul A. Wagner in 2017 and is headquartered in Torrance, CA.
| Head office | United States |
| CEO | Paul Wagner |
| Employees | 14 |
| Founded | 2017 |
| Website | www.fortebiorx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


